Precision Medicine for Neurodevelopmental Disorders

STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD)

Find out more

Autism Spectrum Disorder statistics

A highly common condition 10 million patients in USA + EU
Lack of clear characteristics 80% of cases are idiopathic
No treatment 0 treatments address core symptoms
High economic burden Cost of ASD was $268 billion in 2015 in USA

Matching patients with personalized treatments

STALICLA’s first precision medicine STP1 aims to serve the distinct subgroup of ASD-Phen1 patients. STP1 had entered a clinical Phase 1b trial in December 2020 in the US.

Matching patients with personalized treatments

STALICLA's discovery technology for precision medicine

STALICLA has developed a first-in-class neurodevelopmental disorders -focused AI technology disrupting drug discovery and development approaches in the field.

Find out more

Search for content on Stalicla...